Scienza e Tecnologia
Transine Therapeutics Closes Extended Seed Funding of £9.1 million co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to advance its novel class of therapeutic RNAs
Transine is based on the pioneering work of world-renowned geneticists Professors Stefano Gustincich and Piero Carninci who identified a new functional and naturally occurring class of long non-coding RNAs, named SINEUPs.
SINEUPs® bind in a highly specific manner to their target mRNA to elevate the level of a protein by enhancing protein translation. The attributes of synthetic SINEUPs®, universality, specificity and tunability, together with safety controls, afford this platform broad applicability with the potential to address diseases which have been beyond the reach of small molecules, conventional biologics or gene therapies. Transine's technology massively extends the druggable proteome and represents an entirely unique mechanism of action for currently hard-to-treat diseases.
The modular nature of the technology enables Transine to rapidly design SINEUPs® with high specificity for almost any target for which a mRNA is present. The action of SINEUPs® on translation is controlled and the resulting increase in protein expression is maintained within a physiological range. Their size is optimised to enable a delivery-agnostic approach of therapeutic SINEUPs® that includes delivery as naked oligonucleotides, or via the use of viral vectors such as Adeno-associated virus (AAV), or non-viral systems.
"
" ," commented . " ."
" added. ."
In connection with the financing, Rob Woodman , Senior Partner at Takeda Ventures, and Christian Jung , Partner at the DDF have joined Transine's Board.
Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs . The company's pioneering technology is expected to offer an entirely unique mechanism of action for currently hard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases which have been beyond the reach of small molecules, conventional biologics or gene therapies.
Transine, which was founded in 2020 and is headquartered in Cambridge UK , is backed by Takeda Ventures, Inc. and the Dementia Discovery Fund.
For more information, please visit: www.transinetx.com
and are trademarks of Transine Therapeutics Limited.
Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited, a global, values-based, R&D driven biopharmaceutical leader headquartered in Japan . TVI's mission is to identify, help create and support the development of therapeutic innovation in alignment with Takeda's own strategic imperatives. We do this by investing in technology and product concepts, and highly effective teams that can turn ideas into reality. Our primary focus is on medium to longer term returns in the form of product and technology successes for our portfolio companies and capital gains for the financial institutions we work with.
The Dementia Discovery Fund (DDF) is a £250m specialist venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias including Alzheimer's disease. The DDF brings significant capital and domain expertise to enable talented entrepreneurs to bring therapeutics addressing one of the world's largest unmet medical needs to the clinic – ultimately aiming to generate significant returns for its investors. The DDF is enabled by its networks and influential group of investors including some leading pharmaceutical companies (Biogen, Eli Lilly and Co., GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), along with AARP, Aegon, Bill Gates , British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, the UK Government's Department of Health and Social Care, and the charity Alzheimer's Research UK. The Fund is managed by SV Health Investors. Learn more at www.TheDDFund.com
SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow's healthcare breakthroughs. The SV family of funds invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.7 billion in assets under management and a truly transatlantic presence with offices in Boston and London , SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 200 companies with more than 90 of these having achieved successful acquisitions or IPOs. For more information, please see www.svhealthinvestors.com
Dr Sarah Cole , VP of R & D and Operations
info@Transinetx.com
Sylvie Berrebi , David Dible , Frazer Hall
transinetx@citigatedewerogerson.com
T: +44 (0)20 7638 9571